Imagion Biosystems has released “Preliminary Report and Appendix 4E for the year ended 31 December 2018.
View Appendix 4E and Preliminary Report.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal